The Impact of Primary Tumor Volume on Survival of Patients with Non-Surgically Treated Advanced-Stage Hypopharyngeal Cancer- Retrospective Study and Literature Overview

被引：0
|
作者：
Jakovljevic, Sasa [1 ,2 ]
Djordjevic, Vladimir [1 ,2 ]
Tomanovic, Nada [1 ,3 ]
Arsovic, Nenad [1 ,2 ]
Dudvarski, Zoran [1 ,2 ]
Ursulovic, Tamara [4 ]
Laketic, Darko [1 ,5 ]
Jovanovic, Katarina [2 ]
Arsovic, Konstantin [2 ]
Radivojevic, Nemanja [1 ,2 ]
机构：
[1] Univ Belgrade, Fac Med, Belgrade 11000, Serbia
[2] Univ Clin Ctr Serbia, Clin Otorhinolaryngol & Maxillofacial Surg, Belgrade, Serbia
[3] Inst Pathol, Belgrade, Serbia
[4] Inst Oncol & Radiol Serbia, Belgrade, Serbia
[5] Inst Anat, Belgrade, Serbia
来源：
INDIAN JOURNAL OF OTOLARYNGOLOGY AND HEAD & NECK SURGERY | 2025年 / 77卷 / 01期
关键词：
Advanced hypopharyngeal cancer; Cancer prognosis; Non-surgical treatment; Tumor volume; Survival; SQUAMOUS-CELL CARCINOMA; ADVANCED HEAD; NECK-CANCER; LARYNX CANCER; PROGNOSTIC-FACTORS; LOCAL-CONTROL; RADIOCHEMOTHERAPY; CHEMORADIATION; PRESERVATION; RADIOTHERAPY;
D O I：
10.1007/s12070-024-05139-z
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
To determine the prognostic value of tumor volume in predicting the survival in patients with stage III-IV of hypopharyngeal carcinoma. We studied 71 patients with advanced stage of hypopharyngeal carcinoma. The volume of primary tumor was calculated by approximation of the ellipsoid volume. Correlation between carcinoma volume and demographic, clinical and carcinoma characteristics has shown that male patients and patients consuming alcohol had greater tumor volumes. The median of overall survival was at 12 months (95% CI: 9.25-14.75); the median of progression-free survival was at 9 months (95% CI: 6.6-11.3). ROC Curve Analysis of carcinoma volumes in outcome prediction shows that the cutoff of 14.69 had the sensitivity of 61% and specifics of 89%. Based on significant independent impact of tumor volume on survival, it is important to include this parameter among possible new treatment protocols.
引用
收藏
页码：184 / 193
页数：10
相关论文
共 50 条
  • [41] A Pilot Study of Texture Analysis of Primary Tumor [18F]FDG Uptake to Predict Recurrence in Surgically Treated Patients with Non-small Cell Lung Cancer
    Nakajo, Masatoyo
    Jinguji, Megumi
    Shinaji, Tetsuya
    Aoki, Masaya
    Tani, Atsushi
    Nakabeppu, Yoshiaki
    Nakajo, Masayuki
    Sato, Masami
    Yoshiura, Takashi
    MOLECULAR IMAGING AND BIOLOGY, 2019, 21 (04) : 771 - 780
  • [42] A Pilot Study of Texture Analysis of Primary Tumor [18F]FDG Uptake to Predict Recurrence in Surgically Treated Patients with Non-small Cell Lung Cancer
    Masatoyo Nakajo
    Megumi Jinguji
    Tetsuya Shinaji
    Masaya Aoki
    Atsushi Tani
    Yoshiaki Nakabeppu
    Masayuki Nakajo
    Masami Sato
    Takashi Yoshiura
    Molecular Imaging and Biology, 2019, 21 : 771 - 780
  • [43] Prognostic impact of epidermal growth factor receptor status on overall survival of advanced gastric cancer patients treated with standard chemotherapy: A Japanese multicenter collaborative retrospective study
    Kadowaki, S.
    Fuse, N.
    Kuboki, Y.
    Kuwata, T.
    Nishina, T.
    Ooki, A.
    Goji, T.
    Yamanaka, T.
    Ochiai, A.
    Ohtsu, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S635 - S635
  • [44] Effects of primary tumor resection on the survival of patients with stage IV extrathoracic metastatic non-small cell lung cancer: A population-based study
    Sun, Zewen
    Sui, Xizhao
    Yang, Fan
    Wang, Jun
    LUNG CANCER, 2019, 129 : 98 - 106
  • [45] A phase 1 study in patients with advanced non-small cell lung cancer treated with stereotactic radiotherapy to the primary tumor combined with durvalumab and tremelimumab.
    Kievit, Hanneke
    Muntinghe-Wagenaar, M. Benthe
    Ubbels, Fred
    Wijsman, Robin
    Hijmering-Kappelle, Lucie
    Hiddinga, Birgitta
    Groen, Harry J. M.
    Kerstjens, Huib A. M.
    Van der Wekken, Anthonie J.
    Hiltermann, T. Jeroen Jeroen Nicolaas
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Metabolic tumor volume after two cycles of chemotherapy in patients treated for advanced-stage Hodgkin Lymphoma: analysis of the German Hodgkin Study Group phase III HD18 and HD21 trials
    Kobe, C.
    Kaul, H.
    Schneider, G.
    Fuchs, M.
    Eich, H.
    Rosenbrock, J.
    Baues, C.
    Roth, K.
    Drzezga, A.
    van Heek, L.
    Dietlein, M.
    Borchmann, P.
    Ferdinandus, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S234 - S234
  • [47] Metabolic tumor volume on FDG-PET/CT is a possible prognostic factor for Stage I lung cancer patients treated with stereotactic body radiation therapy: a retrospective clinical study
    Takahashi, Noriyoshi
    Yamamoto, Takaya
    Matsushita, Haruo
    Sugawara, Toshiyuki
    Kubozono, Masaki
    Umezawa, Rei
    Ishikawa, Yojiro
    Kozumi, Maiko
    Katagiri, Yu
    Tasaka, Syun
    Takeda, Kazuya
    Takeda, Ken
    Dobashi, Suguru
    Jingu, Keiichi
    JOURNAL OF RADIATION RESEARCH, 2016, 57 (06) : 655 - 661
  • [48] The surgical resection of the primary tumor increases survival in patients with EGFR-mutant advanced non-small cell lung cancer: a tertiary center cohort study
    Ying-Yuan Chen
    Po-Lan Su
    Wei-Li Huang
    Chao-Chun Chang
    Yi-Ting Yen
    Chien-Chung Lin
    Yau-Lin Tseng
    Scientific Reports, 12 (1)
  • [49] The surgical resection of the primary tumor increases survival in patients with EGFR-mutant advanced non-small cell lung cancer: a tertiary center cohort study
    Chen, Ying-Yuan
    Su, Po-Lan
    Huang, Wei-Li
    Chang, Chao-Chun
    Yen, Yi-Ting
    Lin, Chien-Chung
    Tseng, Yau-Lin
    SCIENTIFIC REPORTS, 2022, 12 (01):
  • [50] Does palliative resection of primary tumor in stage IV colorectal cancer improve survival? An invited commentary on"Survival outcome of palliative primary tumor resection for colorectal cancer patients with synchronous liver and/or lung metastases: A retrospective cohort study in the SEER database by propensity score matching analysis"
    Liu, Xiaoshuang
    Mei, Zubing
    INTERNATIONAL JOURNAL OF SURGERY, 2020, 82 : 208 - 209
12345